Navigation Links
Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
Date:12/18/2007

SAN MARINO, Calif., Dec. 18 /PRNewswire/ -- Epeius Biotechnologies Corporation announced today their appreciation of the accomplishments of their contemporaries in 2007, a truly remarkable year in terms of biomedical research, scholarship, and gonzo journalism. It was a year in which a definitive meeting entitled "In Vivo Barriers to Gene Delivery" was held at the prestigious Cold Spring Harbor Laboratory, where Nobel laureate James Watson presides, or shall we say presided. The meeting served to inform the public and the scientific community that there were actual reasons that the much heralded promise of gene therapy had thus far failed to deliver. Perhaps, if the title of the meeting had been changed to "In Vivo Solutions to Gene Delivery," the scientists of Epeius Biotechnologies might have attended.

*(LOGO 72dpi: Send2Press.com/mediaboom/logo-epeius_72dpi.jpg)

2007 was a year that the 'experts' of all things targeted published a remarkable review article in Nature (Nature Reviews, Genetics, 2007, 8:573-587) entitled "Engineering Targeted Viral Vectors for Gene Therapy." Among the flotsam and jetsam of adenoviral shipwrecks, and the ruminative discourses on "Obstacles to Systemic Targeting," was an intriguing preface stating that "the first clinical trials have already begun to take place," and a brief notation that may be of considerable scientific interest. And we quote, "A third example is represented by the first and so far only targeted vector that has been tested in the clinic: the retroviral vector Rexin-G, which expresses a cytocidal dominant-negative form of cyclin G1." The article goes as far as to mention the fact that a number of clinical studies have "demonstrated the effectiveness of the vector" in the crucible of clinical medicine.

Ironically, 2007 is also the year in which the much acclaimed and heavily subsidized National Gene Vector Laboratories (NGVL) -- whose mission and "primary goal" as an academic vector production facility and national resource was ostensibly to provide clinical grade vectors for clinical gene transfer protocols -- has closed its doors and announced the discontinuance of its programs, while all the world wonders. This same year, 2007, is the year that Rexin-G(R), the world's first and so far only targeted injectable genetic medicine that was designed, engineered, manufactured, validated, tested, and approved for the treatment of otherwise intractable metastatic cancers; the first and so far only one of the plethora of targeted biologics that exhibits broad spectrum anti-cancer activity when administered as a single therapeutic agent, advances alone toward product registration worldwide. So it appears that those of our academic colleagues should continue to teach and tell, while those who can actually do, should continue to do just that.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its lead products and proprietary targeted delivery systems. Credited with innovations ranging from gene discovery, to designer therapeutic genes, to pathotropic (disease-seeking) targeting, to ultra high-performance vector engineering, to advanced biopharmaceutical manufacturing and bioprocess development, Epeius Biotechnologies is well positioned to "launch" its enabling platform technologies for the benefit of cancer patients worldwide. Meanwhile, rapid advances in clinical drug development provide Epeius with a unique opportunity for early revenues from the sale of its lead product to the Philippines and reciprocating ASEAN countries -- thus demonstrating the high growth potential of a small biotechnology company while maintaining the lowered risk profile of a biopharmaceutical company with a high-value, late-stage product.

More information: http://www.epeiusbiotech.com

Rexin-G is a U.S. registered trademark of Epeius Biotechnologies Corporation.

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com


'/>"/>
SOURCE Epeius Biotechnologies Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
2. Most Women With HIV and Their Health Care Providers Have Not Discussed How HIV Might Affect Them Differently Than Men
3. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
4. Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
5. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
6. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
7. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
8. Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
9. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
10. ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Research and Markets has announced the addition of the ... ... energy-based aesthetic devices market to grow at a CAGR of 8.12% ... Aesthetic Devices Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:3/29/2017)... , March 29, 2017  BioSpecifics Technologies ... and continues to develop collagenase based-therapies with a ... (CCH) marketed as XIAFLEX ®  in the U.S. ... will present a corporate overview at the upcoming ... Wednesday, April 5, 2017 at 8:00 a.m. ET ...
(Date:3/29/2017)... , Mar. 29, 2017 Research ... Navigation Systems Market 2014 - 2025" report to their ... ... reach USD 303.7 million by 2025. Increasing geriatric population prone ... demand for orthopedic navigation systems over the forecast period. Osteoarthritis ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... ARI Network Services, Inc. (NASDAQ: ARIS) ... eligible dealer websites for its network of more than 650 U.S.-based dealers. Rhino, a ... equipment including rotary and flail mowers and cutters, rear blades, post hole diggers, pasture ...
(Date:3/29/2017)... FL (PRWEB) , ... March 30, 2017 , ... Grass pollen is the main cause ... allergic to the stuff. The season for grass pollen runs from May to July each ... a hay fever victim to do? HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an ...
(Date:3/29/2017)... ... ... Brand EXOUS Bodygear announced today a special sale price for the EX-701 Knee ... the price will be only $19.97. The EXOUS Bodygear 65cm exercise ball ... $19.97). , The special promotional prices are to help individuals get their products at ...
(Date:3/29/2017)... ... March 29, 2017 , ... Based on research from ... employers face in trying to balance both short-term and long-term benefits demands. ... to the growing complexity, companies are finding that the short-term strategies used to ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... and other outpatient facilities, and who are the most active developers? , ... Revista and Healthcare Real Estate Insights (HREI) found that outpatient medical real estate ...
Breaking Medicine News(10 mins):